Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …

With safety concerns about increasing bleeding, off-label underdosing of non-vitamin K
antagonist anticoagulants (NOACs) is common in East Asian patients with atrial fibrillation …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background Dose adjustment of non‐vitamin K antagonist oral anticoagulants (NOAC s) is
indicated in some patients with atrial fibrillation (AF), based on selected patient factors or …

Objectives To describe (i) the trend in oral anticoagulant (OAC) use following the
introduction of non-vitamin K antagonist oral anticoagulant (NOAC) therapy for stroke …

Aims To examine the long-term persistence and safety of the non-vitamin-K-antagonist oral
anticoagulants (NOACs) dabigatran (D), rivaroxaban (R) and apixaban (A) in patients with …